A. Gabriele

Molecular Diagnosis ofp53Mutations inGastric Carcinoma byTouchPreparation

E. Ricevuto, C. Ficorella, C. Fusco, 1996 .

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer

F. di Costanzo, A. Gabriele, F. Cognetti, 2007, Current medical research and opinion.

Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.

E. Ricevuto, P. Marchetti, C. Ficorella, 1996, The American journal of pathology.

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)

F. Costanzo, A. Gabriele, F. Cognetti, 2004 .

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC).

F. di Costanzo, A. Gabriele, F. Cognetti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.

A. Gabriele, D. Giannarelli, V. Ferraresi, 2005, Journal of experimental & clinical cancer research : CR.

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.

M. Pino, A. Gabriele, F. Cognetti, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[Intraperitoneal chemotherapy].

E. Ricevuto, P. Marchetti, C. Ficorella, 1994, La Clinica terapeutica.